Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Growth Is Accelerating As Industry Transformation Continues
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Growth From $2.51 Billion In 2026 To $4.93 Billion By 2030 At A CAGR Of 18.4%
Recent years have witnessed rapid expansion in the market for ribonucleic acid (rna)-based oncolytic therapies. According to projections, the market is expected to increase from $2.12 billion in 2025 to $2.51 billion in 2026, marking a compound annual growth rate (CAGR) of 18.7%. This historical growth can be explained by advances in cancer virology research, a deeper understanding of tumor immunology, the development of clinical trial infrastructure, rising funds dedicated to oncology research, and the initial successes seen in oncolytic virus studies.
The market for ribonucleic acid (RNA)-based oncolytic therapies is projected to experience substantial expansion over the coming years. By 2030, its value is anticipated to reach $4.94 billion, reflecting a compound annual growth rate (CAGR) of 18.4%. This forecasted growth is driven by several factors, including a higher number of approvals for RNA-based cancer treatments, an increased demand for personalized oncology approaches, the broadening of immuno-oncology development programs, greater funding directed toward gene and cell therapies, and improvements in RNA delivery technologies. Key developments shaping the forecast period encompass progress in RNA virus engineering, a growing trend toward combining oncolytic therapies, an intensified emphasis on stimulating immune responses, the emergence of tumor-specific RNA treatments, and the deeper incorporation of precision oncology tools.
Download A Free Sample Report For Comprehensive Market Insights:
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Demand Drivers: What Is Fueling Industry Growth?
The upward trend in the adoption of personalized medicine is anticipated to fuel the expansion of the RNA-based oncolytic therapy market moving forward. Personalized medicine involves tailoring medical interventions to the unique genetic characteristics of each patient, thereby boosting effectiveness and minimizing unwanted side effects. Its usage is on the rise as a growing number of healthcare providers and institutions recognize how targeted therapies and precision diagnostics can improve patient outcomes. Within cancer care, RNA-based oncolytic therapy is significant because it supports the shift toward personalized medicine by offering customized treatment strategies. To illustrate, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization advocating for individualized medical care, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a sharp increase from 6 in 2022. Consequently, this growing embrace of personalized medicine is propelling the RNA-based oncolytic therapy market forward.
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Segment Outlook: Which Categories Are Expanding The Fastest?
The ribonucleic acid (rna)-based oncolytic therapy market covered in this report is segmented –
1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, Other Therapy Types
2) By Route Of Administration: Intravenous, Intratumoral, Other Route Of Administrations
3) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Applications
4) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Other End-Users
Subsegments:
1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA), Non-Replicating mRNA, Circular RNA (circRNA)-Based mRNA therapy
2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA, Nanoparticle-Delivered siRNA, Conjugated siRNA
3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys
4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Innovation Trends: Which Developments Are Transforming The Industry?
Major industry players in the ribonucleic acid (RNA)-based oncolytic therapy sector are actively working on technological innovations, specifically using synthetic messenger RNA (mRNA) technology to boost how effectively tumors are targeted, strengthen immune responses, and deliver more accurate and enduring outcomes in cancer treatment. Synthetic messenger RNA (mRNA) technology itself is a biotechnological method where custom-made mRNA sequences are designed and administered, prompting cells to manufacture specific therapeutic proteins for treating diseases like cancer. In one example from June 2024, CSPC Pharmaceutical Group Limited, a pharmaceutical firm based in China, secured regulatory clearance in China to begin clinical trials for SYS6020, its cancer cell therapy built on synthetic mRNA. This progress marks a significant milestone in the nation’s mRNA therapeutics field. SYS6020 relies on mRNA-lipid nanoparticle technology to precisely target and eliminate myeloma cancer cells while keeping side effects low, and it also shows promise for treating certain autoimmune conditions.
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Key Companies And Competitive Benchmarking
Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.
Access The Complete Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Report:
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna)-based oncolytic therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
